ARV-6723
Pipeline Category
Pharmaceutical
Short Description / Indication
Arvinas dosed the first patient in a Phase 1/2 clinical trial for ARV-6723 on September 28, 2026, marking it as the first-ever HPK1 PROTAC degrader to enter clinical trials in the United States.
Licensees
| Company Name | Company Website URL |
|---|---|
| Arvinas | https://www.arvinas.com/ |
Pharmaceutical Status